DGX: Jefferies Maintains Buy Rating, Raises Price Target April 2026

Jefferies maintained its Buy rating on Quest Diagnostics (DGX) on April 21, 2026, while raising the price target to $225 from $220. The DGX analyst rating reflects confidence in the diagnostic testing leader’s growth trajectory. At the time of the call, DGX traded at $205.04, representing upside potential to the new target. Quest Diagnostics operates 55,000 employees across a network of labs and patient service centers. The company serves hospitals, health plans, employers, and clinicians with routine and advanced clinical testing services.

Jefferies Maintains Conviction on DGX Analyst Rating

Analyst Action and Price Target Increase

Jefferies held its Buy rating steady while boosting the price target by $5 to $225. This move signals analyst confidence in Quest Diagnostics’ operational execution and market positioning. The price target raise reflects positive momentum in the diagnostic testing sector. DGX stock closed at $205.04, offering roughly 9.7% upside to the new target. The maintained Buy rating underscores Jefferies’ belief that Quest Diagnostics will continue delivering shareholder value through its diversified service offerings and strong cash generation.

Market Context and Stock Performance

DGX has delivered strong year-to-date returns, up 18.24% through April 2026. The stock trades at a P/E ratio of 23.42, reflecting investor appetite for healthcare diagnostics. Volume surged to 2.4 million shares, nearly double the average daily volume of 1.1 million. The 52-week range spans $164.65 to $213.50, showing DGX’s resilience within the healthcare sector. Jefferies’ maintained stance aligns with broader analyst consensus, where 6 analysts rate Buy and 4 rate Hold on the stock.

Meyka AI Grades DGX with B+ Rating

Comprehensive Scoring Methodology

Meyka AI rates DGX with a grade of B+, reflecting solid fundamentals and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests Quest Diagnostics is a quality business with reasonable valuation and execution risk. Meyka’s proprietary algorithm weighs multiple dimensions: S&P 500 comparison (11%), sector metrics (16%), industry standing (16%), financial growth (12%), key metrics (16%), forecasts (8%), analyst consensus (14%), and fundamental growth (7%). These grades are not guaranteed and we are not financial advisors.

Financial Strength Indicators

Quest Diagnostics demonstrates solid operational metrics. The company generated $16.82 in operating cash flow per share and $12.05 in free cash flow per share on a trailing-twelve-month basis. Return on equity stands at 14.1%, indicating efficient capital deployment. The debt-to-equity ratio of 0.95 reflects moderate leverage. Dividend yield of 0.81% provides income to shareholders, with a payout ratio of 35% leaving room for reinvestment and buybacks.

Revenue Growth and Profitability Trends

Fiscal Year 2025 Performance

Quest Diagnostics posted 11.78% revenue growth in fiscal 2025, reaching $102.53 per share in annual revenue. Operating income surged 19.09%, demonstrating operating leverage. Net income climbed 13.89%, translating to $9.31 earnings per share. Gross profit margin expanded to 33.23%, while operating margin reached 14.31%. These metrics underscore DGX’s ability to scale operations and improve profitability. Free cash flow growth accelerated 49.5% year-over-year, signaling strong cash generation and capital efficiency.

Valuation and Forward Outlook

At $205.04, DGX trades at 2.04x price-to-sales and 22.34x forward P/E. The company’s $22.7 billion market cap positions it as a healthcare leader. Meyka’s AI-powered forecasts project DGX reaching $223.64 in five years and $237.52 in seven years. Near-term monthly forecasts suggest $199.87, indicating potential consolidation. The stock’s technical setup shows RSI at 65.06, suggesting moderate momentum without extreme overbought conditions.

Analyst Consensus and Market Positioning

Broader Analyst Coverage

Jefferies’ maintained Buy rating aligns with the broader analyst consensus. Six analysts rate DGX as Buy, while four maintain Hold ratings. No analysts rate the stock as Sell or Strong Sell, reflecting confidence in Quest Diagnostics’ business model. The consensus rating translates to a 3.0 score on a 5-point scale, indicating a lean toward positive sentiment. This consensus provides comfort to investors considering DGX as a core healthcare holding.

Industry Leadership and Competitive Moat

Quest Diagnostics operates the largest diagnostic testing network in the United States. The company’s 55,000 employees serve millions of patients annually through labs, patient service centers, and mobile units. Brands like AmeriPath, Dermpath Diagnostics, and ExamOne strengthen market position. The company’s diversified revenue streams—routine testing, advanced clinical testing, anatomic pathology, and life insurance risk assessment—reduce concentration risk and support resilience.

Technical Setup and Near-Term Catalysts

Chart Patterns and Momentum Indicators

DGX’s technical picture shows mixed signals. The RSI at 65.06 indicates moderate upward momentum without extreme overbought conditions. The MACD histogram at 0.75 suggests positive momentum, though the MACD line remains slightly negative at -0.29. Bollinger Bands show the stock trading near the middle band at $196.32, with upper resistance at $202.85 and lower support at $189.80. The ADX of 15.61 indicates no strong directional trend, suggesting consolidation before the next move.

Upcoming Earnings and Catalysts

Quest Diagnostics will report earnings on July 28, 2026, providing the next major catalyst. Investors will scrutinize revenue growth, margin expansion, and free cash flow generation. Management commentary on healthcare utilization trends, pricing power, and M&A opportunities will influence sentiment. The maintained Buy rating from Jefferies suggests confidence that DGX will deliver results supporting the $225 price target by year-end.

Final Thoughts

Jefferies’ maintained Buy rating and $225 price target on Quest Diagnostics underscore confidence in the company’s diagnostic testing leadership and financial execution. DGX’s 11.78% revenue growth, 49.5% free cash flow acceleration, and 14.1% return on equity demonstrate operational strength. Meyka AI’s B+ grade reflects solid fundamentals, though the 23.42 P/E ratio warrants monitoring for valuation. The stock’s $205.04 price offers reasonable entry for long-term healthcare investors seeking exposure to essential diagnostic services. With six analysts rating Buy and earnings due July 28, DGX appears positioned for continued upside. However, investors should conduct thorough due diligence, as past performance does not guarantee future results. The maintained rating signals analyst conviction, but market conditions and company execution remain critical variables.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.